This was confirmed by mapping the accessibility of regulatory binding regions of direct NRF2 target genes that had previously been identified by chromatin immunoprecipitation and sequencing (ChIP–seq) analysis of human A549 lung cancer cells (Fig. 2B) [32]. This evidence concerns the gene NFE2L2 and lung carcinoma.